EVENTS | VIEW CALENDAR
Agilent tool enhances integrity of genomics experiments
SANTA CLARA, Calif.—This winter saw the announcement by Agilent Technologies Inc. that it would aid those conducting genomics experiments to “enhance integrity” by helping ensure quality of tissue samples. That comes by way of the addition of a new feature to Agilent’s Genomic DNA ScreenTape assay—the DNA Integrity Number (DIN).
The feature is designed to ensure the quality of genomics experiments generally, but especially next- generation sequencing (NGS). It reportedly builds on Agilent’s technology for assessing the integrity of RNA—the RNA Integrity Number (RIN), which Agilent describes as having “become a market-leading standard.”
With the new software feature, the Agilent Genomic DNA ScreenTape assay is now said to provide an objective measure of DNA integrity for a wide range of samples. This includes not just intact samples from fresh tissue but even the highly degraded samples often obtained from formalin-fixed, paraffin-embedded tissues. Agilent expects the DIN to play a key role in determining the quality of samples as they enter the NGS workflow, allowing researchers to better define their genomic DNA samples, standardize their integrity assessment and potentially streamline their sequencing workflow.
Agilent notes that the ability to accurately assess the quality of DNA samples is becoming more important as researchers engage in ever-larger NGS studies. The company also theorizes that DIN could prove invaluable at biobanks, as a tool for measuring archival quality.
Agilent is making DIN freely available as a software upgrade.